chronic wound treatment News
-
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
-
Italian excellence in the treatment of ulcers and wounds
Since its foundation in June 2011, THERESON has combined research and technological and scientific development with the business idea. THERESON believes that technology can be a complementary aid to the treatment and treatment of acute and chronic pathologies. However, it is necessary that each therapeutic medical device is designed in response to the specific needs of the patient, doctor and ...
-
Microbion Corporation today announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria (NTM) at the Colorado Mycobacteria Conference 2022: Focus on NTM
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
-
Amniox Donates $10,000 to American Diabetes Association to Further Scientific Research into Treatment Options for Chronic Wounds
Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue products, announced today that it has gifted the American Diabetes Association (ADA) with a $10,000 donation to support scientific research and prediabetes education. Amniox has been a longtime proponent for the advancement of clinical research of this type. In November 2020, ...
-
Coloplast and the World Diabetes Foundation prevent amputations in India
Coloplast"s donation programme Access to Healthcare just signed a contract with the World Diabetes Foundation (WDF) about a new healthcare project in India. The project aims to improve the treatment of diabetic wounds. "Every single day, 110 Indians have a foot or part of their leg amputated due to diabetic foot ulcers, and an unknown number die before they are even diagnosed," says Per Ole ...
-
Takeover of terraplasma medical GmbH by the Viromed Group
The majority takeover of terraplasma medical GmbH by Viromed Plasma GmbH, a member of the Viromed Group, was announced today. terraplasma GmbH will continue to hold shares in terraplasma medical GmbH in order to contribute its expertise in the field of cold atmospheric plasmas in the future. The common goal of Viromed and terraplasma is to establish terraplasma medical as the world's leading ...
-
Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
-
Next Science and 3M Donate $300,000 of Breakthrough Wound Treatment to Jacksonville-Area Charities
Next Science (ASX:NXS), an innovative medical technology company that is the leader in treating biofilm-based infections in humans, announced today that it has donated $300,000 worth of BlastX™ Antimicrobial Wound Gel to The Save A Leg, Save A Life Foundation in Ponte Vedra. The donation will support the foundation’s mission of reducing lower extremity amputations and improving wound ...
-
SANUWAVE Health Announces Expansion of Ametus Group Distribution Partnership
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in ...
-
SANUWAVE Health Announces Patent Activity from March 2021 to March 2022
SANUWAVE Health, Inc. (SNWV) focuses on the development and commercialization of innovative advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications of shockwave and ultrasound systems in the non-medical field, announced today the patent activity for the past year. For the shockwave technology, the following new ...
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
By healiva SA
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you